Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized ‘FIRST’ study

J.F.R. Robertson(University of Nottingham), Matthew J. Ellis(Washington University in St. Louis), Laura Emerson(AstraZeneca (United Kingdom)), Andrew Dean(AstraZeneca (United Kingdom)), Justin P.O. Lindemann(University Hospital Ostrava), David Feltl(University Hospital Ostrava), Antonio Llombart‐Cussac(Universidad Cardenal Herrera CEU), John Dewar(University Hospital Ostrava), Janusz Rolski(Fundación Instituto Valenciano de Oncología)
Breast Cancer Research and Treatment
October 12, 2012
10.1007/s10549-012-2192-4
Cited by 172

Related Papers

Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2008|3.2k
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
|Journal of Clinical Oncology|2017|1.7k
Letrozole Is More Effective Neoadjuvant Endocrine Therapy Than Tamoxifen for ErbB-1– and/or ErbB-2–Positive, Estrogen Receptor–Positive Primary Breast Cancer: Evidence From a Phase III Randomized Trial
|Journal of Clinical Oncology|2001|1.1k
Whole-genome analysis informs breast cancer response to aromatase inhibition
|Nature|2012|1k
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2
|JAMA Oncology|2019|983